Leerink Partnrs Issues Positive Outlook for HIMS Earnings

Hims & Hers Health, Inc. (NYSE:HIMS) – Leerink Partnrs boosted their Q1 2025 earnings per share estimates for shares of Hims & Hers Health in a report released on Tuesday, February 25th. Leerink Partnrs analyst M. Cherny now anticipates that the company will earn $0.11 per share for the quarter, up from their previous estimate of $0.10. The consensus estimate for Hims & Hers Health’s current full-year earnings is $0.29 per share. Leerink Partnrs also issued estimates for Hims & Hers Health’s Q2 2025 earnings at $0.13 EPS, Q3 2025 earnings at $0.15 EPS, Q4 2025 earnings at $0.17 EPS, FY2025 earnings at $0.56 EPS, FY2026 earnings at $0.75 EPS and FY2027 earnings at $1.15 EPS.

Several other brokerages have also weighed in on HIMS. Piper Sandler boosted their price objective on Hims & Hers Health from $24.00 to $35.00 and gave the company a “neutral” rating in a report on Tuesday. Leerink Partners boosted their price target on Hims & Hers Health from $24.00 to $40.00 and gave the company a “market perform” rating in a report on Tuesday. Citigroup raised their price objective on Hims & Hers Health from $25.00 to $27.00 and gave the stock a “sell” rating in a research note on Tuesday. Canaccord Genuity Group boosted their target price on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a research note on Wednesday, February 19th. Finally, Deutsche Bank Aktiengesellschaft increased their target price on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a report on Wednesday, November 6th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $34.47.

Hims & Hers Health Stock Performance

Shares of Hims & Hers Health stock opened at $41.87 on Thursday. Hims & Hers Health has a 1 year low of $11.20 and a 1 year high of $72.98. The firm’s 50-day simple moving average is $35.89 and its 200-day simple moving average is $26.36. The firm has a market cap of $9.15 billion, a PE ratio of 95.15 and a beta of 1.35.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.02. The firm had revenue of $481.14 million for the quarter, compared to analysts’ expectations of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%.

Institutional Investors Weigh In On Hims & Hers Health

Several hedge funds and other institutional investors have recently added to or reduced their stakes in HIMS. Vanguard Group Inc. boosted its stake in Hims & Hers Health by 11.1% during the 4th quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company’s stock valued at $489,817,000 after purchasing an additional 2,020,722 shares in the last quarter. Farallon Capital Management LLC lifted its holdings in shares of Hims & Hers Health by 64,338.5% in the fourth quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company’s stock valued at $202,556,000 after buying an additional 8,364,000 shares during the period. Renaissance Technologies LLC boosted its stake in Hims & Hers Health by 29.0% during the fourth quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company’s stock valued at $168,079,000 after buying an additional 1,562,302 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its stake in Hims & Hers Health by 192.0% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company’s stock valued at $152,436,000 after buying an additional 4,145,305 shares in the last quarter. Finally, State Street Corp grew its holdings in Hims & Hers Health by 4.7% during the third quarter. State Street Corp now owns 4,626,543 shares of the company’s stock worth $85,221,000 after acquiring an additional 206,078 shares during the period. Institutional investors own 63.52% of the company’s stock.

Insider Transactions at Hims & Hers Health

In related news, CEO Andrew Dudum sold 33,513 shares of the company’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $33.38, for a total value of $1,118,663.94. Following the completion of the sale, the chief executive officer now owns 33,502 shares of the company’s stock, valued at $1,118,296.76. This represents a 50.01 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Melissa Baird sold 85,561 shares of the stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $31.01, for a total transaction of $2,653,246.61. Following the completion of the transaction, the chief operating officer now owns 630,986 shares of the company’s stock, valued at $19,566,875.86. This represents a 11.94 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,097,578 shares of company stock worth $38,080,320. Company insiders own 17.71% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.